Assessing recent milestones in AAV capsid discovery & development for CNS applications

Cell & Gene Therapy Insights 2023; 9(4), 447–453

DOI: 10.18609/cgti.2023.065

Published: 9 May 2023
Mathieu Nonnenmacher

The CNS presents a formidable challenge to gene therapy developers, but the rapidly growing sophistication of viral gene delivery systems offer new hope to the field. David McCall, Senior Editor, BioInsights, speaks to (pictured) Voyager Therapeutics’ Mathieu Nonnenmacher, Vice President, Novel Capsid Discovery about his team’s work in discovering and developing novel AAV capsids with enhanced properties including tissue tropism.